BIAF Stock Summary and Trading Ideas (Bioaffinity Technologies | NASDAQ:BIAF)

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Bioaffinity Technologies trades on the NASDAQ stock market under the symbol BIAF.

As of January 22, 2026, BIAF stock price climbed to $1.39 with 32,557 million shares trading.

BIAF has a beta of -2.97, meaning it tends to be less sensitive to market movements. BIAF has a correlation of 0.08 to the broad based SPY ETF.

BIAF has a market cap of $6.25 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioaffinity Technologies reported $1 million in Revenue and -$4.74 earnings per share. This beat revenue expectation by $35,000 and missed earnings estimates by -$2.04.

In the last 3 years, BIAF traded as high as $119.70 and as low as $1.11.

The top ETF exchange traded funds that BIAF belongs to (by Net Assets): VXF.

BIAF has underperformed the market in the last year with a return of -93.1%, while the SPY ETF gained +15.6%. In the last 3 month period, BIAF fell short of the market, returning -50.9%, while SPY returned +3.1%. However, in the most recent 2 weeks BIAF has outperformed the stock market by returning +7.8%, while SPY returned 0.0%.

BIAF support price is $1.22 and resistance is $1.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIAF shares will trade within this expected range on the day.